ORIC Pharma's Shares Plunge As Initial ORIC-101 Data In Prostate Cancer Fails To Impress Investors

ORIC Pharmaceuticals Inc ORIC announced initial data from Phase 1b study evaluating ORIC-101 in combination with enzalutamide in patients with metastatic prostate cancer progressing on enzalutamide.
Data were presented at AACR-NCI-EORTC.
Related Link: Oric Pharma's ORIC-101 Shows Tumor Regression, Prolonged Stable Disease in Multiple Heavily Pretreated Tumors.
The two patients with low glucocorticoid receptor (GR) came off treatment at less than two months.
In contrast, the six patients with moderate to high GR demonstrated prolonged time on treatment.
ORIC-101 plasma concentrations provided target coverage, consistent suppression of key GR biomarkers, and no evidence of drug-drug interaction impacting enzalutamide.
The Company also presented preclinical data for ORIC-114 that demonstrated brain exposure and antitumor activity in preclinical studies of HER2-positive breast cancer.
Related: Oric Pharma To Launch Human Trial For CD73 Inhibitor Program In Q4.
Price Action: ORIC shares are down 35.40% at $12.29 during the market session on the last check Thursday.